Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Jill C. Higgins x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To determine the seroprevalence of antibodies against Coccidioides immitis in healthy horses residing in an area in which the organism is endemic.

Design—Prospective study.

Animals—197 healthy horses (in which coccidioidomycosis had not been previously diagnosed) that resided in an area of Arizona in which coccidioidomycosis is endemic.

Procedure—Of the horses evaluated at the Arizona Equine Medical and Surgical Center during a 6-month period, 197 with no clinical signs of coccidioidomycosis were randomly selected for inclusion in the study; sera were evaluated for IgM and IgG antibodies against C immitis via an immunodiffusion assay (IgGpositive samples were assessed quantitatively). Within 6 months, recheck titer evaluations were attempted for all seropositive horses.

Results—Serum antibodies against C immitis were detected in 8 of 197 horses (seroprevalence, 4.06%). Results of serologic assays were positive for IgG antibodies and negative for IgM antibodies in 7 horses and positive for both IgG and IgM antibodies in 1 horse; reciprocal serum IgG antibody titers were low (none > 8). Follow-up serologic data were obtained from 5 horses; compared with initial findings, horses had become seronegative or titers were unchanged or decreased. Duration of residence in the area was significantly shorter for seropositive horses than for seronegative horses.

Conclusions and Clinical Relevance—Serum antibodies against C immitis may rarely be detected in healthy horses residing in an area in which the disease is endemic; any horse with a detectable serum antibody titer should be reevaluated after an interval of at least 3 weeks. (J Am Vet Med Assoc 2005;226:1888–1892)

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To characterize signalment, clinical and laboratory findings, treatment, and outcome in horses with rattlesnake envenomation in northern California.

Design—Retrospective case series.

Animals—58 client-owned horses evaluated for rattlesnake envenomation at 2 referral hospitals from 1992 to 2009.

Procedures—Records of horses with rattlesnake envenomation were reviewed, and data concerning signalment, clinical and laboratory findings, treatment, and outcome were collected. In addition, a rattlesnake-bite severity score (RBSS) was assigned to each horse. Variables were compared between horses that survived and those that did not.

Results—The overall mortality rate was 9%. Nine horses received antivenin; no complications were reported and none of the 9 died. The most common laboratory findings associated with severity of envenomation were thrombocytopenia, hypoproteinemia, hyperlactatemia, and a high RBSS.

Conclusions and Clinical Relevance—Most horses in this study had a good prognosis after being bitten by rattlesnakes. Laboratory and clinical examination findings may be useful for identifying horses with a poorer prognosis. Treatment with antivenin may be beneficial and warrants further evaluation.

Restricted access
in Journal of the American Veterinary Medical Association